Media headlines about Cellectar Biosciences (NASDAQ:CLRB) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cellectar Biosciences earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.9050732290295 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

CLRB has been the subject of several recent analyst reports. ValuEngine raised Cellectar Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Zacks Investment Research raised Cellectar Biosciences from a “sell” rating to a “hold” rating in a report on Monday, September 25th.

Cellectar Biosciences (NASDAQ:CLRB) remained flat at $$1.55 during midday trading on Tuesday. 184,151 shares of the company traded hands, compared to its average volume of 214,205. Cellectar Biosciences has a one year low of $1.12 and a one year high of $3.07.

Cellectar Biosciences (NASDAQ:CLRB) last released its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. equities research analysts anticipate that Cellectar Biosciences will post -0.92 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Cellectar Biosciences (CLRB) Stock Price” was reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/11/07/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-cellectar-biosciences-clrb-stock-price.html.

About Cellectar Biosciences

Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.

Insider Buying and Selling by Quarter for Cellectar Biosciences (NASDAQ:CLRB)

Receive News & Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.